The biotech IPO window is officially open. Eleven second-quarter biotech initial public offerings totaling $1 billion — the strongest quarterly biotech market for venture-backed IPOs since third-quarter 2000 — fueled an overall surge in IPOs, according to the National Venture Capital Association and news and data company Thomson Reuters. A total of 21 venture-backed IPOs across industries raised $2.1 billion during the second quarter, according to the "Exit Poll" reported by the NVCA and Thomson Reuters, but VC fundraising declined.
To read the full, original article click on this link: Biotech IPOs surge to 13-year high - San Francisco Business Times
